Physician profile
John P Lee
NPI 1992806699
$4,597.74
in general payments reported to CMS, 2019-2025
29 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $887 · 2021: $627 · 2022: $387 · 2023: $653 · 2024: $501 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $846.43 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $517.53 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $468.21 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $293.07 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $261.92 | 2019-2021 | |
| Abbott Laboratories | $247.34 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.44 | 2019-2021 | |
| Amgen INC. | $237.12 | 2019-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $202.47 | 2020-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $173.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.94 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $148.07 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $145.74 | 2019-2021 | |
| Allergan, INC. | $89.36 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.85 | 2025 | Caplyta |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $76.71 | 2019 | |
| Biogen, INC. | $68.95 | 2020-2021 | |
| Pfizer INC. | $63.24 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $61.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.85 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $32.15 | 2025 | Rexulti |
| Inari Medical, INC. | $27.71 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Lundbeck LLC | $22.24 | 2025 | Vyepti |
| Sun Pharmaceutical Industries INC. | $15.10 | 2020 | |
| Sanofi Pasteur INC. | $14.27 | 2019 | |
| Inspire Medical Systems, INC. | $14.22 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $13.35 | 2024 | Gemtesa |
| Radius Health, INC. | $12.68 | 2019 | |
| Corium, LLC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.